These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30664736)

  • 1. A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.
    Freedland SJ; Howard L; Allen J; Smith J; Stout J; Aronson W; Inman BA; Armstrong AJ; George D; Westman E; Lin PH
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):428-437. PubMed ID: 30664736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
    Chi JT; Lin PH; Tolstikov V; Oyekunle T; Alvarado GCG; Ramirez-Torres A; Chen EY; Bussberg V; Chi B; Greenwood B; Sarangarajan R; Narain NR; Kiebish MA; Freedland SJ
    Prostate; 2021 Jul; 81(10):618-628. PubMed ID: 33949711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).
    Freedland SJ; Allen J; Jarman A; Oyekunle T; Armstrong AJ; Moul JW; Sandler HM; Posadas E; Levin D; Wiggins E; Howard LE; Wu Y; Lin PH
    Clin Cancer Res; 2020 Jun; 26(12):3035-3043. PubMed ID: 32108029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.
    Freedland SJ; Howard LE; Ngo A; Ramirez-Torres A; Csizmadi I; Cheng S; Mack A; Lin PH
    J Urol; 2021 Dec; 206(6):1411-1419. PubMed ID: 34259565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
    Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
    BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
    Cormie P; Galvão DA; Spry N; Joseph D; Chee R; Taaffe DR; Chambers SK; Newton RU
    BJU Int; 2015 Feb; 115(2):256-66. PubMed ID: 24467669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of multidisciplinary interventions in preventing metabolic syndrome and improving body composition in prostate cancer patients treated with androgen deprivation therapy: A systematic review and meta-analysis.
    Yang U; Harikrishna A; Preda V; Chen J
    Clin Nutr ESPEN; 2023 Dec; 58():27-49. PubMed ID: 38057016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
    Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
    BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer.
    Algotar AM; Hsu CH; Chow HH; Dougherty ST; Babiker HM; Marrero DG; Abraham I; Kumar R; Ligibel JA; Courneya KS; Smith TE; Jones PA; Lopez JN; Niemiro G; Ramakumar S; Hoy RD; Mack C; Thomson CA
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):903-909. PubMed ID: 33767355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy.
    Haseen F; Murray LJ; O'Neill RF; O'Sullivan JM; Cantwell MM
    Trials; 2010 Aug; 11():86. PubMed ID: 20704726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
    Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
    Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight Loss for Obese Prostate Cancer Patients on Androgen Deprivation Therapy.
    Wilson RL; Newton RU; Taaffe DR; Hart NH; Lyons-Wall P; Galvão DA
    Med Sci Sports Exerc; 2021 Mar; 53(3):470-478. PubMed ID: 33009195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Almonds vs complex carbohydrates in a weight reduction program.
    Wien MA; Sabaté JM; Iklé DN; Cole SE; Kandeel FR
    Int J Obes Relat Metab Disord; 2003 Nov; 27(11):1365-72. PubMed ID: 14574348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer.
    Newton RU; Taaffe DR; Spry N; Gardiner RA; Levin G; Wall B; Joseph D; Chambers SK; Galvão DA
    BMC Cancer; 2009 Jun; 9():210. PubMed ID: 19563641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
    BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
    Mahalingam D; Hanni S; Serritella AV; Fountzilas C; Michalek J; Hernandez B; Sarantopoulos J; Datta P; Romero O; Pillai SMA; Kuhn J; Pollak M; Thompson IM
    Oncotarget; 2023 Jun; 14():622-636. PubMed ID: 37335291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.
    Lee CE; Leslie WD; Lau YK
    BMC Cancer; 2012 Mar; 12():103. PubMed ID: 22436542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight loss via a low-carbohydrate diet improved the intestinal permeability marker, zonulin, in prostate cancer patients.
    Lin PH; Howard L; Freedland SJ
    Ann Med; 2022 Dec; 54(1):1221-1225. PubMed ID: 35486445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy.
    Kiwata JL; Dorff TB; Todd Schroeder E; Salem GJ; Lane CJ; Rice JC; Gross ME; Dieli-Conwright CM
    BMJ Open; 2017 Jul; 7(7):e016910. PubMed ID: 28698349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.